Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX)

CUSIP: 22053A107

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class
Equity / Common Stock, par value $0.0001 par value
Shares outstanding
55,541,178
Total 13F shares
20,143,303
Share change
+8,350,640
Total reported value
$67,479,982
Put/Call ratio
258%
Price per share
$3.35
Number of holders
67
Value change
+$28,429,772
Number of buys
46
Number of sells
9

Quarterly Holders Quick Answers

What is CUSIP 22053A107?
CUSIP 22053A107 identifies QNCX - Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX) as of Q4 2025

As of 31 Dec 2025, Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX) was held by 67 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 20,143,303 shares. The largest 10 holders included Nantahala Capital Management, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., VANGUARD GROUP INC, Woodline Partners LP, MILLENNIUM MANAGEMENT LLC, IEQ CAPITAL, LLC, Almitas Capital LLC, SUPERSTRING CAPITAL MANAGEMENT LP, STEMPOINT CAPITAL LP, and RENAISSANCE TECHNOLOGIES LLC. This page lists 67 institutional shareholders reporting positions in this security for the Q4 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.